Regarding the possible effects of metabolic preferences of melanoma tumors on the efficacy of targeted therapy, it is of interest that mutant BRAF inhibition might be more efficacious in tumors with higher glycolytic index [170, 171]. Here, BRAF is linked to melanoma.